Long-term safety and efficacy of esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression – an Asian sub-group analysis from the SUSTAIN-2 study.
Hong Jin Jeon 1, 2, 3, Po-Chung Ju 4, 5, Ahmad Hatim Sulaiman 6, Salina Abdul Azis 7, Jong-Woo Paik 8, Wilson Tan 9*, Daisy Bai 10, Cheng-Ta Li 11, 12
1Department of Psychiatry, Depression Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 2Korea Psychological Autopsy Center (KPAC), Seoul, Korea, 3Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul, Korea, 4Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, 5Department of Psychiatry, Chung Shan Medical University Hospital, Taichung, Taiwan, 6Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 7Department of Psychiatry and Mental Health, Hospital Kuala Lumpur. Kuala Lumpur, Malaysia, 8Department of Psychiatry, Kyung Hee University College of Medicine, Seoul, Korea, Seoul, Korea, 9Regional Medical Affairs, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore, 10Statistics & Decision Sciences, Janssen Research & Development, LLC, Shanghai, China., 11Division of Community & Rehabilitation Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan, 12Functional Neuroimaging and Brain Stimulation Lab, National Yang-Ming University, Taipei, Taiwan